UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day (read more)
License Agreement
Discover 2020: UTRF Annual Report
UTRF is delighted to share Discover 2020, which celebrates our innovators and UTRF’s impact on innovation, new venture formation, and corporate engagement for the University of Tennessee. Download accessible PDF. View past annual reports.
From Discovery to Biopharmaceutical Startup: UTGSM Innovators Demonstrate Progress in Therapeutics for Systemic Amyloidosis
A team of researchers from the University of Tennessee Graduate School of Medicine has spent more than two decades investigating systemic amyloidosis, a rare and often fatal disorder with few treatments. Their work played an integral role in moving discoveries out of the lab and into clinical trials, helping launch a biopharmaceutical company focused on (read more)